Jason Fangusaro, MD

The leaders in the pediatric low-grade glioma (pLGG) field offer their concluding insights and perspectives on the future of pLGG management.

The panel of pediatric low-grade glioma (pLGG) experts delves into the potential adverse events associated with targeted therapies, outlining common reactions and their severity, while also sharing their strategies and best practices for toxicity management.

The key opinion leaders analyze a second clinical scenario, focusing on a patient with a BRAF V600E mutation in their pediatric low-grade glioma (pLGG).

The panel presents alternative treatment options and key considerations for the discussed clinical scenario, elaborating on the factors that influence their decision-making process.

The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG).

The panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.

The panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.

The panel of medical experts examines the roles of radiation therapy and targeted therapies in the management of progressive pediatric low-grade gliomas (pLGG).

The panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.

The panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.

The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.

The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.

The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current best practices and therapeutic approaches.

The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.

Experts examine the molecular diversity of pediatric low-grade gliomas, exploring its significance for diagnostic approaches and therapeutic strategies.

Key opinion leaders offer a comprehensive overview of pediatric low-grade glioma, encompassing its epidemiology, characteristic disease presentation, differentiation from adult manifestations, and impact on patients' quality of life.